pI: 8.3209 |
Length (AA): 263 |
MW (Da): 29494 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 238 | 1csh (A) | 204 | 437 | 50.00 | 0 | 1 | 1.50104 | -0.79 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_128590)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G58740 | citrate synthase 1 |
Arabidopsis thaliana | AT2G42790 | citrate synthase 3 |
Arabidopsis thaliana | AT3G58750 | citrate synthase 2 |
Dictyostelium discoideum | DDB_G0276965 | citrate synthase |
Dictyostelium discoideum | DDB_G0287281 | citrate synthase |
Dictyostelium discoideum | DDB_G0267426 | citrate synthase |
Drosophila melanogaster | Dmel_CG14740 | CG14740 gene product from transcript CG14740-RA |
Escherichia coli | b0720 | citrate synthase |
Escherichia coli | b0333 | 2-methylcitrate synthase |
Mycobacterium leprae | ML2130c | PROBABLE CITRATE SYNTHASE I GLTA2 |
Mycobacterium tuberculosis | Rv1131 | Probable methylcitrate synthase PrpC |
Mycobacterium tuberculosis | Rv0896 | Probable citrate synthase I GltA2 |
Mycobacterium ulcerans | MUL_0255 | type II citrate synthase |
Mycobacterium ulcerans | MUL_2494 | citrate synthase |
Neospora caninum | NCLIV_024780 | citrate synthase, putative |
Neospora caninum | NCLIV_021820 | Citrate synthase (EC 2.3.3.1), related |
Oryza sativa | 4328812 | Os02g0232400 |
Plasmodium vivax | PVX_211290 | unspecified product |
Plasmodium vivax | PVX_226290 | unspecified product |
Schmidtea mediterranea | mk4.054382.01 | |
Schmidtea mediterranea | mk4.046581.00 | |
Toxoplasma gondii | TGME49_203110 | citrate synthase, putative |
Toxoplasma gondii | TGME49_263130 | citrate synthase, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0735 | citrate synthase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu1151 | Mycobacterium tuberculosis | non-essential | nmpdr |
b0333 | Escherichia coli | non-essential | goodall |
b0720 | Escherichia coli | non-essential | goodall |
TGME49_203110 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_263130 | Toxoplasma gondii | Probably non-essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.